Rubius Therapeutics is a clinical-stage biotechnology company based in Cambridge, MA, specializing in the development of programmable epigenomic mRNA medicines for precise control of gene regulation and cellular function. Through their OMEGA platform, they utilize computational genomics, machine learning, and artificial intelligence to design innovative therapeutics that target a wide range of diseases.
With a focus on patient needs, Rubius Therapeutics is driven by a world-class team of ambitious and resilient leaders, thinkers, and scientists. Their pipeline consists of diverse biology, tissue, and disease types, aiming to address previously challenging medical conditions and transform the field of precision medicine.
Generated from the website